Diagnosis and treatment of cutaneous paraneoplastic disorders

Dermatologic Therapy

Volumn 23, Issue 6, 2010, Pages 662-675

  Abreu Velez, Ana Maria ^a   Howard, Michael S ^a  

^a Georgia Dermatopathology Associates   (United States)

Author keywords

paraneoplastic disorders; skin manifestations

Indexed keywords

NUCLEAR FACTOR I; SEROTONIN;

ACANTHOSIS NIGRICANS; ACANTHOSIS PALMARIS; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ANGIONEUROTIC EDEMA; BASAL CELL NEVUS SYNDROME; BAZEX SYNDROME; BIRT HOGG DUBE SYNDROME; CARCINOID SYNDROME; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; COWDEN SYNDROME; DERMATOMYOSITIS; DISEASE ASSOCIATION; ERYTHEMA; ERYTHEMA GYRATUM REPENS; GENE MUTATION; GLUCAGONOMA; HUMAN; ICHTHYOSIS; MALIGNANT ATROPHIC PAPULOSIS; NEOPLASM; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PAGET SKIN DISEASE; PARANEOPLASTIC PEMPHIGUS; PARANEOPLASTIC SYNDROME; PITYRIASIS; PITYRIASIS ROTUNDA; PYODERMA GANGRENOSUM; REVIEW; SKIN DISEASE; SKIN METASTASIS; SUPERIOR CAVA VEIN SYNDROME; WERNER SYNDROME; XANTHOMA; YELLOW NAIL SYNDROME;

HUMANS; PARANEOPLASTIC SYNDROMES; PREDICTIVE VALUE OF TESTS; SKIN; SKIN DISEASES; TREATMENT OUTCOME;

EID: 78449283963     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2010.01371.x     Document Type: Review

References (83)

1. Sariya D, Ruth K, Adams-McDonnell R, et al. Clinicopathologic correlation of cutaneous metastases: experience from a cancer center. Arch Dermatol 2007: 143: 613-620.
2. Krathen RA, Orengo IF, Rosen T,. Cutaneous metastasis: a meta-analysis of data. South Med J 2003: 96: 164-167.
3. Rosen T,. Cutaneous metastases. Med Clin North Am 1980: 65: 885-900.
4. Brownstein MH, Helwig EB,. Metastatic tumors of skin. Cancer 1972: 29: 1298-1307.
5. Connor DH, Taylor HB, Helwig EB,. Cutaneous metastases of renal cell carcinoma. Arch Pathol 1963: 76: 339-346.
6. Lookingbill DP, Spangler N, Helm KF,. Cutaneous metastases in patients with metastatic carcinoma: a retrospective study of 4020 patients. J Am Acad Dermatol 1993: 29: 228-236.
7. Hidaka T, Ishii Y, Kitamura S,. Clinical features of skin metastases from lung cancer. Intern Med 1996: 35: 459-462.
8. Chanda JJ,. Extramammary Paget's disease: prognosis and relationship to internal malignancy. J Am Acad Dermatol 1985: 13: 1009-1014.
9. Dalberg K, Hellborg H, Wärnberg F,. Paget's disease of the nipple in a population based cohort. Breast Cancer Res Treat 2008: 111: 313-319.
10. Stacpoole PW,. The glucagonoma syndrome: clinical features, diagnosis, and treatment. Endocr Rev 1981: 2: 347-361.
11. Fitzpatrick TB, Johnson RA, Wolff K, et al. Color atlas and synopsis of clinical dermatology, 4th ed. New York, NY: McGraw Hill Professional, 2001: 493.
12. Callen JP,. Skin signs of internal malignancy. In:, Callen JP, Jorizzo JL, Bologni JL, eds. Dermatological signs of internal disease, 3rd ed. Philadelphia, PA: WB Saunders, 2003: 95-104.
13. Braverman IM,. Skin manifestations of internal malignancy. Clin Geriatr Med 2002: 18: 1-19, v.
14. Berkowitz I, Hodkinson HJ, Kew MC, et al. Pityriasis rotunda as a cutaneous marker of hepatocellular carcinoma: a comparison with its prevalence in other diseases. Br J Dermatol 1989: 120: 545-549.
15. Wilkinson DS,. Necrolytic migratory erythema with carcinoma of the pancreas. Trans St John's Hosp Dermatol Soc 1973: 59: 244-250.
16. Kheir SM, Omura EF, Grizzle WE, Herrera GA, Lee I,. Histologic variation in the skin lesions of the glucagonoma syndrome. Am J Surg Pathol 1986: 10: 445-453.
17. Braverman IM,. "Cutaneous manifestations of internal malignant tumors" by Becker, Kahn and Rothman, June 1942. Commentary: Migratory necrolytic erythema. Arch Dermatol 1982: 118: 784-798.
18. Van Beek AP, De Haas ER, Van Vloten WA, Lips CJ, Roijers JF, Canninga-van Dijk MR,. The glucagonoma syndrome and necrolytic migratory erythema: a clinical review. Eur J Endocrinol 2004: 151 (5): 531-537.
19. Toro JR, Wei MH, Glenn GM, et al. BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dube' syndrome: a new series of 50 families and a review of published reports. J Med Genet 2008: 45: 321-331.
20. Nickerson ML, Warren MB, Toro JR, et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell 2002: 2: 157-164.
21. Linehan WM, Pinto PA, Srinivasan R, et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res 2007: 13: 671s-679s.
22. Zbar B, Alvord WG, Glenn G, et al. Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dube syndrome. Cancer Epidemiol Biomarkers Prev 2002: 11: 393-400.
23. Gorlin RJ,. Nevoid basal-cell carcinoma syndrome. Medicine (Baltimore) 1987: 66: 98-113.
24. Cowan R, Hoban P, Kelsey A, et al. The gene for the naevoid basal cell carcinoma syndrome acts as a tumour-suppressor gene in medulloblastoma. Br J Cancer 1997: 76: 141-145.
25. Albrecht S, Goodman JC, Rajagopolan S, et al. Malignant meningioma in Gorlin's syndrome: cytogenetic and p53 gene analysis. Case report. J Neurosurg 1994: 81: 466-471.
26. Seracchioli R, Colombo FM, Bagnoli A, et al. Primary ovarian leiomyosarcoma as a new component in the nevoid basal cell carcinoma syndrome: a case report. Am J Obstet Gynecol 2003: 188: 1093-1095.
27. Yilmaz B, Goldberg LH, Schechter NR, et al. Basal cell nevus syndrome concurrent with adenoid cystic carcinoma of salivary gland. J Am Acad Dermatol 2003: 48: S64-S66.
28. Schulz-Butulis BA, Gilson R, Farley M, et al. Nevoid basal cell carcinoma syndrome and non-Hodgkin's lymphoma. Cutis 2000: 66: 35-38.
29. Beddis IR, Mott MG, Bullimore J,. Case report: nasopharyngeal rhabdomyosarcoma and Gorlin's naevoid basal cell carcinoma syndrome. Med Pediatr Oncol 1983: 11: 178-179.
30. Bolognia JL, Brewer YP, Cooper DL,. Bazex syndrome (acrokeratosis paraneoplastica). An analytic review. Medicine (Baltimore) 1991: 70: 269-280.
31. Taher M, Grewal P, Gunn B, Tonkin K, Lauzon G,. Acrokeratosis paraneoplastica (Bazex syndrome) presenting in a patient with metastatic breast carcinoma: possible etiologic role of zinc. J Cutan Med Surg 2007: 11: 78-83.
32. Karabulut AA, Sahin S, Sahin M, Eksioglu M, Ustün H,. Paraneoplastic acrokeratosis of Bazex (Bazex's syndrome): report of a female case associated with cholangiocarcinoma and review of the published work. J Dermatol 2006: 33: 850-854.
33. Bolognia JL,. Bazex syndrome: acrokeratosis paraneoplastica. Semin Dermatol 1995: 14: 84-89.
34. Valdivielso M, Longo I, Suárez R, Huerta M, Lázaro P,. Acrokeratosis paraneoplastica: bazex syndrome. J Eur Acad Dermatol Venereol 2005: 19: 340-344.
35. Varas-Lorenzo MJ, Muñoz-Agel F, Espinós-Pérez JC, Bardají-Bofill M,. Gastrointestinal carcinoid tumors. Rev Esp Enferm Dig 2010: 102: 533-537.
36. Goljan E,. Pathology. 2009. 2nd ed Mosby Elsevier, Rapid Review series.
37. Lookingbill DP, Spangler N, Sexton FM,. Skin involvement as the presenting sign of internal carcinoma. A retrospective study of 7316 cancer patients. J Am Acad Dermatol 1990: 22: 19-26.
38. Caplin ME, Buscombe JR, Hilson AJ, et al. Carcinoid tumour. Lancet 1998: 352: 799-805.
39. Eng C,. Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet 2000: 37 (11): 828-830.
40. Lloyd KM, Dennis M,. Cowden's disease. A possible new symptom complex with multiple system involvement. Ann Intern Med 1963: 58: 136-142.
41. Chu EC, Tarnawski AS,. PTEN regulatory functions in tumor suppression and cell biology. Med Sci Monit 2004: 10: RA235 - RA241.
42. Callen JP,. Dermatomyositis and malignancy. Clin Dermatol 1993: 11: 61-65.
43. Callen JP,. The value of malignancy evaluation in patients with dermatomyositis. J Am Acad Dermatol 1982: 6: 253-259.
44. Chow WH, Gridley G, Mellemkjaer L, et al. Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control 1995: 6: 9-13.
45. Boyd AS, Neldner KH, Menter A,. Erythema gyratum repens: a paraneoplastic eruption. J Am Acad Dermatol 1992: 26: 757-762.
46. Appell ML, Ward WQ, Tyring SK,. Erythema gyratum repens. A cutaneous marker of malignancy. Cancer 1988: 62: 548-550.
47. Stone SP, Buescher LS,. Life-threatening paraneoplastic cutaneous syndromes. Clin Dermatol 2005: 23: 301-306.
48. Boyd AS, Neldner KH, Menter A,. Erythema gyratum repens: a paraneoplastic eruption. J Am Acad Dermatol 1992: 26: 757-762.
49. Griffin LJ, Massa MC,. Acquired ichthyosis and pityriasis rotunda. Clin Dermatol 1993: 11: 27-32.
50. James W, Berger T, Elston D,. Andrews' diseases of the skin: clinical dermatology, 10th ed. Saunders, 2005.
51. Freedberg I, et al. Fitzpatrick's Dermatology in General Medicine, 6th ed. USA: McGraw-Hill, 2003.
52. Aram H,. Acquired ichthyosis and related conditions. Int J Dermatol 1984: 23: 458-461.
53. Van Dijk MR,. Ichthyosiform atrophy of the skin associated with internal malignant diseases. Dermatologica 1963: 127: 413-428.
54. Marchuk DA, Saulino AM, Tavakkol R, et al. cDNA Cloning of the Type-1 neurofibromatosis gene - complete sequence of the NF1 gene product. Genomics 1991: 11: 931-940.
55. Gutmann DH, Giovannini M,. Mouse models of neurofibromatosis 1 and 2. Neoplasia 2002: 4: 279-290.
56. Feldkamp MM, Angelov L, Guha A,. Neurofibromatosis Type 1 peripheral nerve tumors: aberrant activation of the Ras pathway. Surg Neurol 1999: 51: 211-218.
57. Hannan F, Ho I, Tong JJY, Zhu YH, Nurnberg P, Zhong Y,. Effect of Neurofibromatosis type I mutations on a novel pathway for adenylyl cyclase activation requiring neurofibromin and Ras. Hum Mol Genet 2006: 15: 1087-1098.
58. Ozawa T, Araki N, Yunoue S, et al. The Neurofibromatosis Type 1 Gene Product Neurofibromin Enhances Cell Motility by Regulating Actin Filament Dynamics via the Rho-ROCK-LIMK2-Cofilin Pathway. J Biol Chem 2005: 280: 39524-39533.
59. Hartz RS, Daroca PJ,. Clinical-pathologic conference: Cutaneous paraneoplastic pemphigus associated with benign encapsulated thymoma. J Thorac Cardiovasc Surg 2003: 125: 400-406.
60. Anhalt GJ, Kim SC, Stanley JR, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990: 323: 1729-1735.
61. Niimi Y, Kawana S, Hashimoto T, et al. Paraneoplastic pemphigus associated with uterine carcinoma. J Am Acad Dermatol 2003: 48: S69-S72.
62. Mutasim DF, Pelc NJ, Anhalt GJ,. Paraneoplastic pemphigus. Dermatol Clin 1993: 11: 473-481.
63. Yeh SW, Ahmed B, Sami N, Ahmed AR,. Blistering disorders: diagnosis and treatment. Dermatol ther 2003: 16: 214-223.
64. Powell FC, Su WP, Perry HO,. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol 1996: 34: 395-409.
65. Bennett ML, Jackson JM, Jorizzo JL, et al. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore) 2000: 79: 37-46.
66. Powell FC, Schroeter AL, Su WP, et al. Pyoderma gangrenosum: a review of 86 patients. Q J Med 1985: 55: 173-186.
67. Cicardi M, Zingale LC, Pappalardo E, et al. Autoantibodies and lymphoproliferative diseases in acquired C1-inhibitor deficiencies. Medicine (Baltimore) 2003: 82: 274-281.
68. Reinhold U, Bruske T, Schupp G,. Paraneoplastic urticaria in a patient with ovarian carcinoma. J Am Acad Dermatol 1996: 35: 988-989.
69. Cohen PR, Kurzrock R,. Sweet's syndrome: a neutrophilic dermatosis classically associated with acute onset and fever. Clin Dermatol 2000: 18: 265-282.
70. Chan HL, Lee YS, Kuo TT,. Sweet's syndrome: systemic signs and symptoms and associated disorders. Int J Dermatol 1994: 33: 425-432.
71. Degos R, Delort J, Tricot R,. Dermatite papulosquameuse atrophiante. Bulletin la Société française dermatologie de syphiligraphie de ses filiales 1942: 49: 148-150.
72. Ball E, Newburger A, Ackerman AB,. Degos' disease: a distinctive pattern of disease, chiefly of lupus erythematosus, and not a specific disease per se. Am J Dermatopathol 2003: 25: 308-320.
73. High WA, Aranda J, Patel SB, Cockerell CJ, Costner MI,. Is Degos' disease a clinical and histological end point rather than a specific disease? J Am Acad Dermatol 2004: 50: 895-899.
74. Cohen PR, Grossman ME, Almeida L, et al. Tripe palms and malignancy. J Clin Oncol 1989: 7: 669-678.
75. Armstrong BA, Perez CA, Simpson JR, et al. Role of irradiation in the management of superior vena cava syndrome. Int J Radiat Oncol Biol Phys 1987: 13: 531-539.
76. Sato K, Goto M, Nishioka K, et al. Werner's syndrome associated with malignancies: five case reports with a survey of case histories in Japan. Gerontology 1988: 34: 212-218.
77. Salk D, Au K, Hoehn H, et al. Cytogenetics of Werner's syndrome cultured skin fibroblasts: variegated translocation mosaicism. Cytogenet Cell Genet 1981: 30: 92-107.
78. Epstein CJ, Martin GM, Schultz AL, et al. Werner's syndrome: a review of its symptomatology, natural history, pathologic features, genetics and relationship to the natural aging process. Medicine (Baltimore) 1966: 45: 177-221.
79. Hrabko RP, Milgrom H, Schwartz RA,. Werner's syndrome with associated malignant neoplasms. Arch Dermatol 1982: 118: 106-108.
80. Singla A,. Normolipemic papular xanthoma with xanthelasma. Dermatol Online J 2006: 12: 3-19.
81. Guin JD, Elleman JH,. Yellow nail syndrome. Possible association with malignancy. Arch Dermatol 1979: 115: 734-735.
82. Iqbal M, Rossoff LJ, Marzouk KA, et al. Yellow nail syndrome: resolution of yellow nails after successful treatment of breast cancer. Chest 2000: 117: 1516-1518.
83. Gupta AK, Davies GM, Haberman HF,. Yellow nail syndrome. Cutis 1986: 37: 371-374.